Maze Therapeutics Inc (MAZE) Stock Price, Quote & News

Company Profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 850 5070

Website: www.mazetx.com

Address:

171 Oyster Point Blvd, Suite 300, South San Francisco, United States

MorganHoratio May. 8 at 1:36 PM

Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: $HYPR - 898,720 $LYEL - 293,256 $MAZE - 1,388,583 $GLUE - 684,275 $OSCR - 481,988 Google's Q1 13F reveals a sharp focus: Cybersecurity Bedrock + AI Bio-Engineering! The stake in $HYPR is a massive signal—in a 2026 defined by AI deepfakes, Google is leaning on $HYPR's passwordless tech to fortify its Gemini ecosystem. Meanwhile, the heavy lifting in $MAZE and $GLUE proves Alphabet is no longer just indexing information, but indexing "cures" through AI-led protein modeling. With $OSCR hitting its profitability inflection point, do you think Google is just building an AI-health moat, or are we looking at the early days of its next multi-billion dollar "Other Bet" breakout? Let's discuss your top small-cap pick!

3 · Reply

OfficialStocktwitsUser May. 5 at 12:37 PM

$MAZE RSI: 45.90, MACD: -2.5639 Vol: 0.83, MA20: 26.88, MA50: 36.54 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

AnthonyTradingWithJesus Apr. 27 at 4:08 AM

$AI $MAZE $JOB $OMEX $CRM Good interview, very bullish, very transparent

1 · Reply

almlk Apr. 8 at 2:11 PM

$SPY $QQQ Start seeing RED in my watch list: $PLTR is the first RED followed by $APP, $MAZE Others start retreating from highs, decrease their gains.

0 · Reply

StreetwiseReports Apr. 7 at 5:17 PM

San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial https://ow.ly/YB7J50YF5RP H.C. Wainwright reiterated its rating and price target on Maze Therapeutics ( $MAZE ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials.

0 · Reply

Quantumup Apr. 2 at 12:12 PM

Guggenheim⬇️ $UNCY's PT to $40, reiterated at Buy and said, We had a chance to catch up with the Unicycive management team yesterday after the company released their 4Q 2025 results earlier in the week. $MAZE TVTX SNY TAK $ARDX Here's what else Guggenheim had to say: https://x.com/Quantumup1/status/2039676564908945610?s=20

0 · Reply

BestNwest Apr. 1 at 8:29 PM

$MAZE price target around 60$

0 · Reply

ItsAGreatDay Apr. 1 at 6:19 PM

$MAZE Two great DOW and NASDAQ up days - MAZE seems dead! What the Crap!

0 · Reply

Quantumup Apr. 1 at 11:36 AM

H.C. Wainwright reiterated $UNCY Buy; $22 $ARDX $MAZE SNY TVTX TAK Here's what H.C. Wainwright had to say in its note to investors: https://x.com/Quantumup1/status/2039304811489718531?s=20

0 · Reply

rob70 Mar. 30 at 2:33 PM

$MAZE May go sub 29...wow.

0 · Reply

Maze Therapeutics reports Q1 EPS (45c), consensus (63c)

May 12, 2026, 4:01 PM EDT - 16 hours ago

Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

2026-04-22T12:10:05.000Z - 21 days ago

Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50

Apr 22, 2026, 12:09 AM EDT - 21 days ago

Maze Therapeutics Announces $150 Million Registered Offering

2026-04-14T11:17:48.000Z - 4 weeks ago

Maze Therapeutics price target lowered to $64 from $68 at Truist

2026-03-31T10:51:36.000Z - 6 weeks ago

Maze Therapeutics price target raised to $58 from $52 at JPMorgan

Mar 26, 2026, 9:40 AM EDT - 6 weeks ago

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-03-25T16:00:16.000Z - 6 weeks ago

Maze Therapeutics falls -29.8%

2026-03-25T15:36:01.000Z - 6 weeks ago

Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James

VRTX

2026-03-25T14:06:47.000Z - 6 weeks ago

Maze Therapeutics falls -33.2%

2026-03-25T13:36:15.000Z - 6 weeks ago

Leerink remains bullish on Maze, says Vertex comparison ‘apples to oranges’

VRTX

2026-03-25T13:25:30.000Z - 6 weeks ago

Maze Therapeutics price target raised to $110 from $60 at H.C. Wainwright

2026-03-25T12:07:43.000Z - 7 weeks ago

Maze Therapeutics reports Q4 EPS (65c), consensus (78c)

2026-03-25T12:07:27.000Z - 7 weeks ago

Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data

2026-03-25T12:00:48.000Z - 7 weeks ago

Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial

Mar 25, 2026, 8:00 AM EDT - 7 weeks ago

Maze Therapeutics Transcript: Study result

Mar 25, 2026, 7:00 AM EDT - 7 weeks ago

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Mar 25, 2026, 7:00 AM EDT - 7 weeks ago

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

2026-03-17T20:16:50.000Z - 2 months ago

Maze Therapeutics initiated with a Buy at Truist

2026-03-16T12:00:26.000Z - 2 months ago

Maze Therapeutics price target raised to $58 from $43 at Wedbush

2026-03-10T08:45:19.000Z - 2 months ago

Maze Therapeutics initiated with an Outperform at Mizuho

Mar 4, 2026, 10:30 AM EST - 2 months ago

Maze Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-04T12:25:05.000Z - 2 months ago

Maze Therapeutics price target raised to $58 from $46 at Guggenheim

Feb 25, 2026, 7:00 AM EST - 2 months ago

Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 3:00 PM EST - 3 months ago

Maze Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-04T22:26:03.000Z - 3 months ago

Maze Therapeutics files automatic mixed securities shelf

Feb 4, 2026, 7:00 AM EST - 3 months ago

Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 12, 2026, 11:15 AM EST - 4 months ago

Maze Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 4 months ago

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 10:25 AM EST - 5 months ago

Maze Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 20, 2025, 7:00 AM EST - 6 months ago

Maze Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 2:00 PM EST - 6 months ago

Maze Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 8:00 AM EST - 6 months ago

Maze Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 4:01 PM EST - 6 months ago

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 7:00 AM EST - 6 months ago

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Nov 4, 2025, 7:00 AM EST - 6 months ago

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

Oct 28, 2025, 4:27 PM EDT - 7 months ago

Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease

Oct 28, 2025, 12:36 PM EDT - 7 months ago

San Francisco is making a comeback. So are these stocks from the City by the Bay

NKTR REAL

Oct 6, 2025, 7:00 AM EDT - 7 months ago

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

Sep 11, 2025, 8:30 AM EDT - 8 months ago

Maze Therapeutics Transcript: Study Result

Sep 11, 2025, 7:35 AM EDT - 8 months ago

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

Sep 11, 2025, 7:30 AM EDT - 8 months ago

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

Sep 2, 2025, 7:00 AM EDT - 9 months ago

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

Aug 27, 2025, 11:31 AM EDT - 9 months ago

National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Jul 10, 2025, 4:05 PM EDT - 10 months ago

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

May 29, 2025, 7:30 AM EDT - 1 year ago

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

May 14, 2025, 4:01 PM EDT - 1 year ago

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

May 13, 2025, 7:30 AM EDT - 1 year ago

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Mar 31, 2025, 7:30 AM EDT - 1 year ago

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Feb 7, 2025, 8:00 AM EST - 1 year ago

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

Jan 31, 2025, 12:33 PM EST - 1 year ago

Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut

Jan 30, 2025, 7:45 PM EST - 1 year ago

Biotech firm Maze Therapeutics raises $140 million in US IPO

Jan 30, 2025, 7:30 PM EST - 1 year ago

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

Jan 27, 2025, 6:31 AM EST - 1 year ago

Maze Therapeutics targets up to $728 mln valuation in US IPO

MorganHoratio May. 8 at 1:36 PM

3 · Reply

OfficialStocktwitsUser May. 5 at 12:37 PM

0 · Reply

AnthonyTradingWithJesus Apr. 27 at 4:08 AM

$AI $MAZE $JOB $OMEX $CRM Good interview, very bullish, very transparent

1 · Reply

almlk Apr. 8 at 2:11 PM

$SPY $QQQ Start seeing RED in my watch list: $PLTR is the first RED followed by $APP, $MAZE Others start retreating from highs, decrease their gains.

0 · Reply

StreetwiseReports Apr. 7 at 5:17 PM

0 · Reply

Quantumup Apr. 2 at 12:12 PM

0 · Reply

BestNwest Apr. 1 at 8:29 PM

$MAZE price target around 60$

0 · Reply

ItsAGreatDay Apr. 1 at 6:19 PM

$MAZE Two great DOW and NASDAQ up days - MAZE seems dead! What the Crap!

0 · Reply

Quantumup Apr. 1 at 11:36 AM

H.C. Wainwright reiterated $UNCY Buy; $22 $ARDX $MAZE SNY TVTX TAK Here's what H.C. Wainwright had to say in its note to investors: https://x.com/Quantumup1/status/2039304811489718531?s=20

0 · Reply

rob70 Mar. 30 at 2:33 PM

$MAZE May go sub 29...wow.

0 · Reply

ChessGM Mar. 30 at 2:02 AM

$MAZE https://youtu.be/hOfAkUcIu5k /

1 · Reply

CAN29 Mar. 28 at 1:01 PM

$MAZE Anyone see a potential call bet, maybe 3-6 weeks out for a bounce🤔

1 · Reply

rob70 Mar. 27 at 2:30 PM

$MAZE terrible trade for me...was ccertain we'd see a bounce but this market is horrific.

0 · Reply

rob70 Mar. 26 at 7:25 PM

$MAZE from up 10% to red. What a shit market.

0 · Reply

ItsAGreatDay Mar. 26 at 2:00 PM

$MAZE Back to $40 by EOW!!! Hoping!

4 · Reply

ItsAGreatDay Mar. 26 at 1:40 PM

$MAZE Why so brutal? Damn!!!!

1 · Reply

Binion Mar. 26 at 1:07 PM

$MAZE I remember when I was 20… lmao

0 · Reply

amule Mar. 26 at 3:07 AM

$MAZE no point trading in a market like this. This fell for no reason at all with all positive news.

0 · Reply

finviz Mar. 26 at 12:41 AM

Most volatile and largest drops today include $MAZE $BATL and $ELAB

0 · Reply

Market Cap	1.27B
Revenue (ttm)	0.00
Net Income (ttm)	-131.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	350,500
Avg Vol	970,174
Day's Range	N/A - N/A
Shares Out	49.76M
Stochastic %K	29%
Beta	2.50
Analysts	Strong Sell
Price Target	$63.55